MILPITAS Feb 11, 2020 (Thomson StreetEvents) -- Edited Transcript of Onto Innovation Inc earnings conference call or presentation Thursday, February 6, 2020 at 9:30:00pm GMT
Onto Innovation Inc. - Senior Director of IR, Corporate Communications & Marketing Research
* Michael P. Plisinski
Onto Innovation Inc. - CEO & Director
* Steven R. Roth
Onto Innovation Inc. - Senior VP of Finance & Administration, CFO and Secretary
* J. Ho
Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector
B. Riley FBR, Inc., Research Division - Associate Analyst
D.A. Davidson & Co., Research Division - MD & Senior Research Analyst
Good day, and welcome to the Onto Innovation Fourth Quarter Earnings Release Conference call. During today's call, there will be a question and answer session. (Operator Instructions) Today's conference is being recorded.
At this time, I would like to turn the conference over to Michael Sheaffer, Investor Relations. Please go ahead, sir.
Michael Sheaffer, Onto Innovation Inc. - Senior Director of IR, Corporate Communications & Marketing Research [2]
Thank you, Karina. Good afternoon, everyone. Onto Innovation issued its 2019 fourth quarter and full year financial results this afternoon, shortly after the market closed. If you have not received a copy of the release, please refer to the company's website at http://www.ontoinnovation.com, where a copy of this release is posted. Joining us on the call today are Michael Plisinski, Chief Executive Officer; and Steven Roth, Chief Financial Officer.
As is always the case, I need to remind you of the safe harbor regulations. Any matters today that are not historical facts, particularly comments regarding the company's future plans, objectives, forecasts and expected performance consist of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such estimates, whether expressed or implied are being made based on currently available information and the company's best judgment at this time. Within these is a wide range of assumptions that the company believes to be reasonable. However, it must be recognized that these statements are subject to a range of certainties that can cause the actual results to vary materially. Thus, the company cautions that these statements are no guarantee of future performance. Risk factors that may impact Onto Innovation's results are currently described in both Rudolph Technologies Form 10-K report and Nanometrics Form 10-K report for the year ended December 2018 as well as other filings with the Securities and Exchange Commission. Onto Innovation does not update forward-looking statements and expressly disclaims any obligation to do so. Today's discussion of our financial results will be presented on a non-GAAP financial basis, unless otherwise specified. A detailed reconciliation between GAAP and non-GAAP results can be found in today's earnings release.
And now I'll go ahead and turn the call over to Mike Plisinski. Mike?
Michael P. Plisinski, Onto Innovation Inc. - CEO & Director [3]
--------------------------------------------------------------------------------
Thank you, Mike. Good afternoon, everyone, and welcome to Onto Innovation's fourth quarter earnings call. I'll start with an update on the most exciting event for the fourth quarter, the merger of Nanometrics and Rudolph Technologies, which resulted in the launch of Onto Innovation. Onto Innovation is positioned to benefit from nearly every major technology inflection across the semiconductor value chain from the continued evolution of advanced nodes in both memory and logic fabs to the growth of specialty devices for sensing and communications and the essential advanced packaging that opens the door for greater levels of integration and performance in a smaller form factor. We closed on this transformational merger in late October. And since then, Onto Innovation team has been working diligently to integrate our businesses and form the foundation for future innovation and shareholder value creation. In these past 3 months, we have integrated our talented and customer support teams in order to more efficiently leverage our combined infrastructure, and ultimately, improve our customers' experience with our portfolio solutions. We have identified and implemented $14 million in annualized synergies and we are confident in ending this year with $20 million of annualized cost synergies with additional synergies to follow. Finally, our technology teams have been busy exploring potential revenue synergies to strengthen our core markets and expand our SAM. Of course, it will take time for these benefits to be fully realized, but the effort is progressing very well.
Turning to the specifics of our fourth quarter, the Onto Innovation team delivered solid results with revenue coming in at $120.6 million, which was above the midpoint of our forecasted range. Non-GAAP earnings per share came in at $0.41 at the high end of our guidance. As a reminder, we will be reporting our results in 3 categories. The first category is advanced semiconductor nodes, which includes DRAM, NAND and logic, including foundry. The second category is specialty devices and advanced packaging, which includes those categories in our nascent silicon wafer manufacturing market. And our third category is software and services.
For the fourth quarter, advanced nodes declined slightly overall. Atlas III+ metrology sales doubled over the third quarter, predominantly to support the ramping of 10-, 7- and 5-nanometer logic nodes by 2 of the top 5 semiconductor manufacturers. The Atlas platform's increased throughput and more sensitive broad spectrum optical metrology is well suited to help customers control the increasingly more complex 3D measurements required for yields at the leading edge. The growth in logic mostly offset the decline in memory we projected last quarter after strong demand from NAND customers in the third quarter.
Revenue from our specialty device and packaging -- advanced packaging segment increased 7% from the third quarter. As a reminder, this is generally a unit volume-driven business, where growth is typically through expansions to meet higher chip volume versus technology transitions. As a result, the business is generally more susceptible to the effects of seasonality with Q4 and Q1 typically being the slower quarters. However, revenue in the fourth quarter reflects a growing demand for 5G-enabled devices with advanced packaging revenue increasing 5%.
The Dragonfly inspection system achieved record revenue in the quarter and enjoyed broad adoption across the most demanding advanced packaging applications, including multiple tools shipped to a top 5 memory manufacturer for stack DRAM packaging applications. Other wins included 2D inspection with clarifying technology and 3D bump inspection for top 5 logic and foundry customers in support of their announced 5G and high-performance computing applications. Rounding out the customer wins, several OSAT customers took delivery of their first Dragonfly system for bump inspection to support expansion of their packaging lines for mobility products. Revenue from silicon wafer manufacturers grew by over 50% in the fourth quarter, driven by record shipments of our QS series FTIR metrology systems to substrate manufacturers worldwide. Also contributing to the growth were multiple shipments of NovusEdge in the quarter, including to a new customer. In the last year, NovusEdge has been adopted by 4 of the top 5 silicon wafer manufacturers and our QS series FTIR is positioned on all of the top 5. We believe this will position us well for continued growth in 2020.
Also during the fourth quarter, we delivered and recognized a second JetStep Lithography System for a panel packaging customer who is increasing capacity for 2020. This customer has developed a reputation for high-quality and high-yielding advanced panel processes and has attracted a growing number of customers for devices, such as power management and RF modules, microcontrollers and FPGAs. This customer is also incorporating our Firefly inspection tool to provide feed-forward metrology data to the JetStep Lithography System using our StepFAST software solution as they begin to move toward high-volume manufacturing in mid-2020.
Finally, rounding out the quarter, our software and services business continues to grow as each company had invested in infrastructure and technology to provide more value-enhancing services to our customers. As mentioned at the start of the call, we see opportunities to leverage our broader infrastructure to improve efficiencies and deliver more value-enhancing services.
In summary, over the full year, our new products helped to strengthen our position in core markets and open opportunities in new markets. The Atlas III+ expanded our optical metrology position across the leading-edge logic and memory customers. We have now secured tooler record positions with leaders in logic, 3D NAND and DRAM, resulting in a more balanced foundation from which to grow in 2020. Likewise, we are pleased with the selection of Dragonfly inspection by 15 new customers in 2019 across diverse markets in advanced packaging and across a wide variety of applications such as packaging RF wireless power devices and automotive.
Shipments of our NovusEdge inspection and FTIR metrology product lines more than doubled from 2018 to 2019. We believe this market will continue to grow and be a more meaningful part of our business in 2020. Combined, these new products resulted in over $130 million of revenue in 2019 and provide a strong base to grow from as we look ahead to 2020.
Specific to the first quarter of 2020, we see specialty devices and packaging segment continuing to grow into the first quarter. We see DRAM spending increasing in the first quarter, offsetting a pause in logic and NAND and leading to revenue in the range of $136 million plus or minus 6%. In this revenue range, earnings per share would be $0.23 to $0.41 per share. The midpoint of this revenue range represents an increase of 13% over the reported fourth quarter after being adjusted downward to reflect the projected impact of the coronavirus on the timing of our shipments to China. Absent that adjustment, we expected our midpoint in the upper half of our guidance range. By now, many of you are aware that the rapid spread of the coronavirus has resulted in a mandated extension of the Chinese Lunar New Year holiday to February 10. Strict quarantine of a number of cities and provinces and other travel restrictions across the country. This has delayed some of our planned shipments in February. Our guidance reflects the best information available from our customers as to when they believe travel restrictions will be lifted and shipments to their factories can resume. It's important to note that we do not see any impact on demand at this time. The impact is only on the timing of shipments. And as we manage through this situation and assess timing, our first priority will be to the safety and well-being of our staff and their families.
Looking more broadly at 2020, we see demand for 5G-enabled devices and high-performance computing sparking a broader recovery in the market. Gartner forecasts that worldwide, mobile phones will see a modest increase this year versus a decline in 2019. Driving the majority of that increase are the 5G-enabled handsets, which Gartner predicts will account for 12% of all mobile phone shipments in 2020, increasing to 43% of all mobile phones in 2022. As a result, we expect to see a number of Onto Innovation markets expand in 2020. The most obvious impact of this growth is in our specialty devices and advanced packaging segment. Underscoring this opportunity is our release from earlier in this -- in the month announcing the receipt of orders for 15 inspection systems from 2 customers rapidly expanding advanced packaging capacity to support wafer-level packaging of 5G devices. We see continued growth in these markets in 2020, driven by volume increases as well as additional devices migrating to advanced packaging. We also see 5G and high-performance computing, benefiting our advanced node segments in which leaders, such as SK Hynix, recently forecast 5G smartphones will drive a 25% increase in DRAM content per phone, while NAND will benefit from 20% increase per phone. And TSMC recently cited growing demand for their 5-nanometer process from 5G processors, RF front-end modules and advanced computing. We expect our advanced semiconductor nodes segment to grow modestly with sustained levels of logic foundry spending and a pickup in memory spending starting with DRAM.
In conclusion, semiconductor markets are becoming more diverse every year. We see chip innovations and cameras, sensing and communications, enabling new customer products such as smart home, smart grids and wearable health monitors. We see innovations in the advanced nodes for both memory and logic, enabling data centers and AI engines to open up entirely new markets such as medicine, autonomous driving and energy. We see a growing number of customers increasing their focus on advanced packaging technology to unlock the full potential of new chip designs and more tightly integrated and high-performing form factors. Across the spectrum, Onto Innovation is an important partner to our customers. Our merger strengthens our ability to provide value-enhancing services to our customers, increase our pace of product innovation and deliver more comprehensive, integrated solutions to challenges further down our customers' road map. We are only at the very start of this journey, but we are committed to maximizing our potential to the benefit of all of our stakeholders, customers, shareholders and our team.
With that, I'll turn the call over to Steve Roth to review the financial highlights.
--------------------------------------------------------------------------------
Steven R. Roth, Onto Innovation Inc. - Senior VP of Finance & Administration, CFO and Secretary [4]
--------------------------------------------------------------------------------
Thanks, Mike. Before I begin my financial remarks today, I want to remind you, as usual, the financial results discussed here will be provided on a non-GAAP basis. And that our non-GAAP presentation for the new merged company no longer excludes stock-based compensation as the former Rudolph financials did. In addition, as detailed in our last conference call, Rudolph was deemed the financial acquirer in the merger. And therefore, the combined financial results presented today represent the results of Rudolph for the full fourth quarter but only the results of former Nanometrics since the closing of the merger on October 25. I recognize that this partial quarter makes comparability of prior period somewhat difficult and I'll try to bridge those differences for comparative purposes to the prior periods.
As Mike mentioned, our reported fourth quarter revenue was $120.6 million, above the midpoint of our guidance. That revenue excludes both $10 million of Nanometrics October shipments and $1.7 million of deferred revenue that would have rolled into the quarter, but was eliminated in the merger accounting. Therefore, on a total quarter basis, as if the merger was completed at the beginning of the quarter, our full quarter revenue would have been $132.3 million. That's a 3% decrease from the $136 million in combined revenue, if you add the 2 separate companies' third quarter reported revenue together.
Breaking the revenue down by market. Revenue from advanced nodes account for 44% of revenue with strength in logic and foundry offset by lower memory business. Specialty devices and advanced packaging customers accounted for 35% of revenue, and the remaining 21% of revenue came from our software and services business. We had 1 customer in the fourth quarter representing 10% or greater sales. As we have discussed, one of the benefits of the merged company is the broad and diverse customer base, with over 150 customers from silicon wafer manufacturers all the way to advanced packaging customers.
Turning to gross margin. Fourth quarter gross margin was 51% and was impacted by the cleanup of inventory items as we prepare to go live with the new ERP system in January, which we did not non-GAAP out. Excluding those inventory adjustments, our Q4 gross margin would have been approximately 52%. As we look forward to our first full combined quarter in Q1, we see the revenue volume per Mike's guidance, or that Mike just provided, and product mix primarily affecting the margin. And therefore, expect our gross margins to be in the range of 50% to 52%.
Fourth quarter operating expenses, as reported, were $40.7 million and excluded $8.7 million of fourth quarter Nanometrics expenses prior to the closing. On a full quarter basis, total operating expenses would have been approximately $49.4 million.
Operating expenses reported by each separate company in the third quarter of 2019, when combined, equaled $51.8 million. Portion of the decrease between the periods is due to the merger synergies, having a partial positive effect on Q4 expenses. Historically, operating expenses increased quarter-over-quarter from Q4 to Q1, as during the first quarter we perform our annual compensation reviews and equity grants and bonus plans and payroll taxes reset for the year. We have also implemented a significant portion of our synergies mainly around business rationalization, streamlining corporate overhead and eliminating duplicative public company costs, which on an annual basis totals $14 million and puts us well on our way to achieving our stated goal of $20 million by the end of 2020. The quarterly benefit of those synergies will partially offset the normal Q1 operating expense increases I just mentioned. And based on that, we are currently forecasting our Q1 operating expenses to be in the range of $49.5 million to $51.5 million. Net income for the fourth quarter was $18.1 million or $0.41 per share and at the higher end of our guidance. That per share amount was based on 43 million diluted shares outstanding due to the deal being closed in the middle of the quarter. For the first quarter, we are estimating a diluted share count of approximately 50.5 million shares in our earnings per share calculations. That share count difference negatively impacts Q1 guidance by approximately $0.04 per share when compared to Q4.
Now turning to cash and investments, which are on a GAAP basis. We ended the year with a cash position of $320.2 million after paying out approximately $25 million in merger expenses. On a 50.5 million diluted share count, that equates to $6.34 per share. As the industry continues to improve and we begin to benefit from the synergies in our operations and improve our working capital metrics, we're targeting cash flow to be approximately 20% of revenue in 2020.
Now I'd like to open the call to questions. Operator?
================================================================================
Questions and Answers
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------
(Operator Instructions) We'll take our first question from Patrick Ho with Stifel.
--------------------------------------------------------------------------------
J. Ho, Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector [2]
--------------------------------------------------------------------------------
Thank you for the color in helping to get the financials in order on a going-forward basis. Mike, first off, in terms of your front-end metrology business, can you give a little bit of color -- one on the NAND flash environment and maybe on the timing of when you believe broader base NAND flash spending will come? And secondly, on the DRAM side, some of the comments you made, I think from the metrology end, obviously, there's been increasing capital intensity trends related to metrology use as layers increase, how do we look at the DRAM market, in -- specifically on the metrology and in terms of capital intensity -- how that plays out?
--------------------------------------------------------------------------------
Michael P. Plisinski, Onto Innovation Inc. - CEO & Director [3]
--------------------------------------------------------------------------------
So I'll start with the 3D NAND. So after relatively strong first several quarters of 2019, we had the pause in the fourth quarter. We see 3D NAND picking -- staying or a little bit pause for the first half and picking up more in the second half. And the magnitude of which could determine, obviously, the strength of the year-over-year comparison. But for sure, strengthening in the second half from what we're seeing.
On the DRAM side, we see a little bit of the opposite. We see stronger demand in the first half, starting in the first quarter. And part of that is bringing in equipment for some of the -- I think, it's well publicized, Samsung has announced Beyontec expansion. And going into the second and third quarter, and you know obviously bring in the metrology equipment sooner than the process equipment to help qualify that process equipment, so -- does that...
--------------------------------------------------------------------------------
J. Ho, Stifel, Nicolaus & Company, Incorporated, Research Division - MD of Technology Sector [4]
--------------------------------------------------------------------------------
Great. That's helpful. Yes, it does. And maybe, Steve, in terms of OpEx management, actually looks really good in Q1 relative to some of the expectations I have. How do you see that progressing? And what I'm trying to get at is the cost synergies are still going to be put into place. I'm sure you're looking at new investments. How do we look at the trends as 2020 progresses for OpEx management?
--------------------------------------------------------------------------------
Steven R. Roth, Onto Innovation Inc. - Senior VP of Finance & Administration, CFO and Secretary [5]
--------------------------------------------------------------------------------
Yes. I mean, I would say you can -- it models down quarter-over-quarter, the way we look at it right now. Obviously, some of the synergies timing come in, like you said, they phase in. But yes, I would say that, right now, the guidance that I gave for Q1 is a high point because, as I said, there's a lot of cost -- some of the costs are not linear. So there's always this uptick in the first quarter. And then I would expect them to trail down from here, Patrick, from that guidance.
--------------------------------------------------------------------------------
Operator [6]
--------------------------------------------------------------------------------
And we'll take our next question from Quinn Bolton with Needham.
--------------------------------------------------------------------------------
Quinn Bolton, Needham & Company, LLC, Research Division - Senior Analyst [7]
--------------------------------------------------------------------------------
Congratulations on the nice results in the first quarter as a combined company. I wanted to start just kind of with WFE and sort of how you see the profile of spending across the advanced nodes and the specialty side of the business first half versus second half. Certainly, sounds like advanced foundry logic, maybe front-half loaded. You talked about NAND being stronger in the second half, DRAM being a little bit more steady in Q2, Q3. So when you put all that together, how do you see the pattern of revenue on a sequential basis or a half-over-half basis in 2020?
--------------------------------------------------------------------------------
Michael P. Plisinski, Onto Innovation Inc. - CEO & Director [8]
--------------------------------------------------------------------------------
You're speaking specifically about us, correct? So we're seeing...
--------------------------------------------------------------------------------
Quinn Bolton, Needham & Company, LLC, Research Division - Senior Analyst [9]
--------------------------------------------------------------------------------
Correct.
--------------------------------------------------------------------------------
Michael P. Plisinski, Onto Innovation Inc. - CEO & Director [10]
--------------------------------------------------------------------------------
Yes. And that will depend, obviously, on customer mix, application strength, market share, et cetera. So from our perspective, we're seeing logic -- so we'll start with logic foundry to give you a kind of a complete picture. Logic foundry has maintained relatively high levels, and we see that continuing into 2020. And then the DRAM we see picking up rather nicely into 2020. And then 3D NAND is really the -- I'd say the wild card a little bit. That's -- certainly, we see a pickup in the second half over the first half and the magnitude of which we'll determine is it going to grow over -- year-over-year or is it going to stay a little bit depressed?
--------------------------------------------------------------------------------
Quinn Bolton, Needham & Company, LLC, Research Division - Senior Analyst [11]
--------------------------------------------------------------------------------
Okay, great. And then second question, you mentioned that without the coronavirus you would have probably guided closer to the middle or upper middle part of the first quarter revenue range. Wondering on that coronavirus effect whether you're seeing delays in the tool deliveries to one of the larger NAND players in China. Is that a specific risk? Or are you just sort of generally trying to be conservative with the March quarter guidance, given everything that's going on with the outbreak?
--------------------------------------------------------------------------------
Michael P. Plisinski, Onto Innovation Inc. - CEO & Director [12]
--------------------------------------------------------------------------------
No, that's a specific risk. That's -- I mean, they're, obviously, right in the center of ground zero. So clearly, we've had a lot of detailed discussions there. And we're working with the customers to, obviously, balance the demands that they still have with the realities of the situation on the ground.
--------------------------------------------------------------------------------
Quinn Bolton, Needham & Company, LLC, Research Division - Senior Analyst [13]
--------------------------------------------------------------------------------
Great. And then last one for me, just as we come through the year. So it sounds like gross margin in the first quarter at 50% to 52%, it sounds like there's some mix or some sort of quarter-specific factors. How do you see that gross margin trending beyond the first quarter?
--------------------------------------------------------------------------------
Steven R. Roth, Onto Innovation Inc. - Senior VP of Finance & Administration, CFO and Secretary [14]
--------------------------------------------------------------------------------
The rest is here:
Edited Transcript of NANO earnings conference call or presentation 6-Feb-20 9:30pm GMT - Yahoo Finance
- Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes - December 18th, 2022
- www.the-scientist.com - December 18th, 2022
- Applications of Nanotechnology - National Nanotechnology Initiative - December 18th, 2022
- Nanotechnology Timeline | National Nanotechnology Initiative - October 29th, 2022
- Nano based drug delivery systems: recent developments and future ... - October 21st, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 16th, 2022
- 'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom - September 16th, 2022
- International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld - September 16th, 2022
- Reebok Nano X2 Adventure Review: A Wild Way to Log Your Workouts - Gear Patrol - August 30th, 2022
- PhD within Particle Engineering job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 306487 - Times Higher Education - August 30th, 2022
- Nanoparticles' Role in Eliminating Cancer Cells - MedTech Outlook - August 22nd, 2022
- The first female astronaut from a North African nation will be a Tunisian military aviator - Atalayar - August 22nd, 2022
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition | npj Digital Medicine - Nature.com - August 22nd, 2022
- Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol - August 14th, 2022
- How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle - August 14th, 2022
- Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and... - July 27th, 2022
- Nanorobots Market to close to USD 19576.43 million with CAGR of 12.23% during the forecast period to 2029 - Digital Journal - July 27th, 2022
- Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development... - July 27th, 2022
- Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire - July 19th, 2022
- Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo... - July 19th, 2022
- Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal - July 11th, 2022
- Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM - July 11th, 2022
- Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine - July 11th, 2022
- Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading... - July 11th, 2022
- Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women - July 11th, 2022
- Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - July 11th, 2022
- $2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News - June 22nd, 2022
- New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The... - June 22nd, 2022
- Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women... - June 22nd, 2022
- An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com - June 13th, 2022
- Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld - June 4th, 2022
- New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace - June 4th, 2022
- Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint... - May 15th, 2022
- Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian - May 2nd, 2022
- Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt... - May 2nd, 2022
- Cancer and Nanotechnology - National Cancer Institute - April 19th, 2022
- Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal - April 19th, 2022
- ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil - April 19th, 2022
- Nano Products Online Store | Nanoproducts, Nanoparticles ... - April 6th, 2022
- The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients - Business Wire - March 25th, 2022
- Space the next frontier for cancer treatment? - Australian Jewish News - March 25th, 2022
- ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of... - January 20th, 2022
- Surface Modification and Size Contribute to Nanoplastic Toxicity - AZoNano - January 20th, 2022
- Frontiers | Nanomedicine: Principles, Properties, and ... - January 5th, 2022
- Nanotechnology In Medicine: Huge Potential, But What Are ... - January 5th, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 5th, 2022
- 2009 show based on conspiracy theories is shared as proof of WHO working on COVID-19 vaccines to create permanent sterility - Factly - January 5th, 2022
- How to Improve Infectious Diseases with Nanotechnology - CIO Applications - January 5th, 2022
- Biodistribution of sphingolipid nanoemulsions with 68Ga | IJN - Dove Medical Press - August 31st, 2021
- Matrix Meats Adds to Team as Interest in Cultivated Meat Grows - PRNewswire - July 21st, 2021
- Nanomedicine in Central Nervous System Injury and Repair Market Report- Trends Key Programs Analysis and Competitive Landscape Analysis The Manomet... - June 23rd, 2021
- Nanomedicine is transforming healthcare innovation - Korea IT Times - June 6th, 2021
- The Future of Cancer Treatment Using Nanotechnology - AZoNano - June 6th, 2021
- Thomas Jefferson Awards Highlight Research and Service to the University - UVA Today - June 6th, 2021
- Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to... - October 31st, 2020
- Nanox Signs With Ambra Health to Enable Image Access and Transfer with US Hospitals and Medical imaging Providers - BioSpace - October 31st, 2020
- Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 29th, 2020
- What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network - September 23rd, 2020
- Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas - August 29th, 2020
- Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving... - August 12th, 2020
- Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace - June 17th, 2020
- Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire - June 17th, 2020
- Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type... - June 15th, 2020
- Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK - June 15th, 2020
- Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -... - June 15th, 2020
- Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY - June 10th, 2020
- Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca - May 24th, 2020
- Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press - May 10th, 2020
- The future of medicine - Switzer Financial News - May 10th, 2020
- All your questions about how to wear a face mask -- answered - Action News Now - April 26th, 2020
- Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance - February 11th, 2020
- Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace - February 11th, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - February 6th, 2020
- The Future Of Nano Medicine - February 6th, 2020
- VVUS Stock Jumps 70% on FDA Nod for New Formulation of Pancreaze - MicroSmallCap - February 6th, 2020
- Is the Lieber Arrest Linked to Military Brain Research and China? - Bryen's Blog - February 6th, 2020
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press - January 10th, 2020
- Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News - January 10th, 2020
- Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News - January 10th, 2020
- Our top 20 features of 2019 - COVER - January 5th, 2020